|
1
|
Gelao L, Criscitiello C, Fumagalli L, et
al: Tumour dormancy and clinical implications in breast cancer. E
cancer medical science. 7:3202013.
|
|
2
|
Ligibel JA and Strickler HD: Obesity and
its impact on breast cancer: tumor incidence, recurrence, survival,
and possible interventions. Am Soc Clin Oncol Educ Book.
2013:52–59. 2013. View Article : Google Scholar
|
|
3
|
Cooney MA, Culleton-Quinn E and Stokes E:
Current knowledge of pain after breast cancer treatment: a
systematic review. Pain Manag Nurs. 14:110–123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Makarem N, Chandran U, Bandera EV and
Parekh N: Dietary fat in breast cancer survival. Annu Rev Nutr.
33:319–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Despas F, Roche H and Laurent G:
Anticancer drug adherence. Bull Cancer. 100:473–484. 2013.(In
French). PubMed/NCBI
|
|
6
|
Khan KH, Yap TA, Yan L and Cunningham D:
Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J
Cancer. 32:253–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma X, Liu L, Nie W, et al: Prognostic role
of caveolin in breast cancer: a meta-analysis. Breast. 22:462–469.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Corben AD: Pathology of invasive breast
disease. Surg Clin North Am. 93:363–392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen WX, Hu Q, Qiu MT, et al: miR-221/222:
promising biomarkers for breast cancer. Tumour Biol. 34:1361–1370.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
O’Toole SA, Beith JM, Millar EK, et al:
Therapeutic targets in triple negative breast cancer. J Clin
Pathol. 66:530–542. 2013. View Article : Google Scholar
|
|
11
|
Zhang X, Li XR and Zhang J: Current status
and future perspectives of PI3K and mTOR inhibitor as anticancer
drugs in breast cancer. Curr Cancer Drug Targets. 13:175–187. 2013.
View Article : Google Scholar
|
|
12
|
Warin R, Xiao D, Arlotti JA, Bommareddy A
and Singh SV: Inhibition of human breast cancer xenograft growth by
cruciferous vegetable constituent benzyl isothiocyanate. Mol
Carcinog. 49:500–507. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heinhuis B, Netea MG, van den Berg WB,
Dinarello CA and Joosten LA: Interleukin-32: a predominantly
intracellular proinflammatory mediator that controls cell
activation and cell death. Cytokine. 60:321–327. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Soyka MB, Treis A, Eiwegger T, et al:
Regulation and expression of IL-32 in chronic rhinosinusitis.
Allergy. 67:790–798. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meyer N, Christoph J, Makrinioti H, et al:
Inhibition of angiogenesis by IL-32: possible role in asthma. J
Allergy Clin Immunol. 129:964–973.e7. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moldenhauer A, Futschik M, Lu H, et al:
Interleukin 32 promotes hematopoietic progenitor expansion and
attenuates bone marrow cytotoxicity. Eur J Immunol. 41:1774–1786.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oh JH, Cho MC, Kim JH, et al: IL-32gamma
inhibits cancer cell growth through inactivation of NF-kappaB and
STAT3 signals. Oncogene. 30:3345–33598. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Felaco P, Castellani ML, De Lutiis MA, et
al: IL-32: a newly-discovered proinflammatory cytokine. J Biol
Regul Homeost Agents. 23:141–147. 2009.PubMed/NCBI
|
|
19
|
Nishida A, Andoh A, Inatomi O and Fujiyama
Y: Interleukin-32 expression in the pancreas. J Biol Chem.
284:17868–178766. 2009. View Article : Google Scholar : PubMed/NCBI
|
